PRINCETON, N.J.--(BUSINESS WIRE)--
Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of nonclinical and clinical data.
“As the leader in PK modeling, Certara is committed to providing its clients with technology solutions that streamline both the drug development and the regulatory submittal processes,” said David Munro, president of Certara’s software division. “To that end, we have developed these new tools and services to remove the time-consuming task of converting data to CDISC format manually. Manual efforts are both time-consuming and more error prone, which can slow the drug approval process.”
The US Food and Drug Administration (FDA) now requires that clinical and nonclinical study data for all new drug applications (NDAs), abbreviated NDAs (ANDAs) and biologics license applications (BLAs) be submitted electronically in CDISC format. On Dec. 17, 2017 that requirement will extend to all investigational new drug applications (INDs).
In 2016, there were 160 NDAs and BLAs, 864 ANDAs, and 786 INDs submitted to the FDA.
Aside from the FDA, Japan’s Pharmaceuticals and Medical Devices Agency has also adopted the CDISC standard for clinical data. In addition, the European Medicines Agency, Korea Ministry of Food and Drug Safety, and the China Food and Drug Administration are considering using CDISC standards.
Certara’s CDISC PK solution includes software, services, and consulting:
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.
Copyright Business Wire 2017